Valuation: Tonix Pharmaceuticals Holding Corp

Market Cap 186M 163M 153M 139M 262M 17.86B 262M 1.83B 706M 9.1B 700M 685M 29.33B P/E 2026 *
-1.09x
P/E 2027 * -1.62x
Enterprise Value 186M 163M 153M 139M 262M 17.86B 262M 1.83B 706M 9.1B 700M 685M 29.33B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 1.68x
Free-Float
99.84%
Yield 2026 *
-
Yield 2027 * -
09-08 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 CI
08-18 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Seth Lederman as Interim Chief Medical Officer CI
08-10 Tonix Pharmaceuticals Holding Corp., Q2 2026 Earnings Call, Aug 10, 2026
08-10 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-03 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
07-21 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
07-15 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
07-13 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
07-13 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
06-29 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
06-29 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
06-25 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
Manager TitleAgeSince
Chief Executive Officer 68 15/11/2007
Director of Finance/CFO 52 31/01/2016
Chief Tech/Sci/R&D Officer 57 03/02/2025
Director TitleAgeSince
Chairman 68 30/09/2011
Director/Board Member 66 11/09/2017
Director/Board Member 81 04/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%+4.41%+54.91%+104.50% 1,028B
-0.19%+1.46%+52.94%+65.41% 651B
+0.20%+2.86%+18.88%+72.18% 466B
+2.24%+5.98%+37.61%+42.44% 346B
+0.90%+3.66%+18.79%+25.03% 266B
+0.48%+7.28%+11.11%+14.70% 259B
+1.95%+4.19%+37.75%+44.83% 208B
-7.65%-5.95%-33.09%-60.76% 191B
+0.30%+4.76%+31.97%+98.58% 186B
Average -0.17%+3.26%+25.65%+45.21% 400.19B
Weighted average by Cap. +0.09%+3.09%+35.56%+62.43%

Financials

2026 *2027 *
Net sales 55M 47.98M 45.15M 41.14M 77.16M 5.27B 77.26M 541M 208M 2.68B 207M 202M 8.65B 111M 96.73M 91.03M 82.94M 156M 10.62B 156M 1.09B 420M 5.41B 416M 407M 17.45B
Net income -169M -147M -139M -126M -237M -16.17B -237M -1.66B -639M -8.24B -634M -620M -26.55B -164M -143M -135M -123M -230M -15.74B -231M -1.62B -623M -8.02B -617M -603M -25.85B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!